NO138683C - Grunnmasse til anvendelse ved fremstilling av et farmasoeytisk preparat med langsom frigjoerelse av den aktive bestanddel - Google Patents

Grunnmasse til anvendelse ved fremstilling av et farmasoeytisk preparat med langsom frigjoerelse av den aktive bestanddel

Info

Publication number
NO138683C
NO138683C NO1969/72A NO196972A NO138683C NO 138683 C NO138683 C NO 138683C NO 1969/72 A NO1969/72 A NO 1969/72A NO 196972 A NO196972 A NO 196972A NO 138683 C NO138683 C NO 138683C
Authority
NO
Norway
Prior art keywords
preparation
basic
active ingredient
slow release
pharmaceutical preparation
Prior art date
Application number
NO1969/72A
Other languages
English (en)
Norwegian (no)
Other versions
NO138683B (no
Inventor
Stewart Thomas Leslie
Original Assignee
Mundipharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mundipharma Ag filed Critical Mundipharma Ag
Publication of NO138683B publication Critical patent/NO138683B/no
Publication of NO138683C publication Critical patent/NO138683C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO1969/72A 1971-06-03 1972-06-02 Grunnmasse til anvendelse ved fremstilling av et farmasoeytisk preparat med langsom frigjoerelse av den aktive bestanddel NO138683C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1883971A GB1405088A (en) 1971-06-03 1971-06-03 Slow release formulation

Publications (2)

Publication Number Publication Date
NO138683B NO138683B (no) 1978-07-17
NO138683C true NO138683C (no) 1978-10-25

Family

ID=10119292

Family Applications (1)

Application Number Title Priority Date Filing Date
NO1969/72A NO138683C (no) 1971-06-03 1972-06-02 Grunnmasse til anvendelse ved fremstilling av et farmasoeytisk preparat med langsom frigjoerelse av den aktive bestanddel

Country Status (18)

Country Link
US (1) US4235870A (OSRAM)
JP (1) JPS569490B1 (OSRAM)
AT (1) AT327390B (OSRAM)
BE (1) BE783661A (OSRAM)
CA (1) CA1009146A (OSRAM)
CH (1) CH577830A5 (OSRAM)
DE (1) DE2224534C3 (OSRAM)
DK (1) DK144306C (OSRAM)
ES (2) ES403435A1 (OSRAM)
FI (1) FI55766C (OSRAM)
FR (1) FR2140217B1 (OSRAM)
GB (1) GB1405088A (OSRAM)
IL (1) IL39430A (OSRAM)
NL (1) NL174619C (OSRAM)
NO (1) NO138683C (OSRAM)
PH (2) PH12136A (OSRAM)
SE (1) SE379636B (OSRAM)
ZA (1) ZA723207B (OSRAM)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1488259A (en) * 1974-08-28 1977-10-12 Scherer Corp R P Method for increasing the bioavailability of digitalis cardiac glycosides
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
US4076804A (en) * 1975-07-18 1978-02-28 Abbott Laboratories Erythromycin therapy
GB1593261A (en) 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
EP0013131A3 (en) * 1978-12-27 1981-01-07 Mundipharma A.G. Pharmaceutical composition in solid dosage form, and process for its production
IE49324B1 (en) * 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4428926A (en) 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release propranolol system
US4428925A (en) 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release glycerol trinitrate
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4432965A (en) * 1982-07-09 1984-02-21 Key Pharmaceuticals, Inc. Quinidine sustained release dosage formulation
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
GB8507779D0 (en) * 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
GB8521350D0 (en) 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
GB2186485B (en) * 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2058111T3 (es) * 1986-06-10 1994-11-01 Euro Celtique Sa Composicion de liberacion controlada de dihidrocodeina.
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US5266331A (en) † 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
BE1009257A3 (nl) * 1995-03-21 1997-01-07 Universiteit Gent Lab Voor Far Farmaceutische matrix.
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US6780437B2 (en) * 2001-10-23 2004-08-24 Upsher-Smith Laboratories, Inc. Coated potassium chloride granules and tablets
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
CA2569958C (en) 2004-06-12 2016-03-22 Jane C. Hirsh Abuse-deterrent drug formulations
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
AU2011346757B2 (en) 2010-12-22 2015-08-20 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
TW201625251A (zh) 2012-04-17 2016-07-16 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法
EA201500742A1 (ru) 2013-02-05 2015-12-30 Пердью Фарма Л.П. Защищенные от нецелевого использования фармацевтические композиции
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
EP3645000A4 (en) 2017-06-30 2021-03-24 Purdue Pharma L.P. METHOD OF TREATMENT AND DOSAGE FORMS THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3108046A (en) * 1960-11-25 1963-10-22 Smith Kline French Lab Method of preparing high dosage sustained release tablet and product of this method
US3133863A (en) * 1961-03-10 1964-05-19 Strong Cobb Arner Inc Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
US3146167A (en) * 1961-10-05 1964-08-25 Smith Kline French Lab Method of preparing sustained release pellets and products thereof
DE1185336B (de) * 1961-12-14 1965-01-14 American Cyanamid Co Verfahren zur Herstellung von pharmazeutischen Praeparaten
NL273962A (OSRAM) * 1962-01-25
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical

Also Published As

Publication number Publication date
IL39430A0 (en) 1972-07-26
BE783661A (fr) 1972-09-18
CA1009146A (en) 1977-04-26
NL174619C (nl) 1984-07-16
SE379636B (OSRAM) 1975-10-20
JPS569490B1 (OSRAM) 1981-03-02
AT327390B (de) 1976-01-26
NL174619B (nl) 1984-02-16
DK144306C (da) 1982-07-12
FR2140217A1 (OSRAM) 1973-01-12
NO138683B (no) 1978-07-17
FR2140217B1 (OSRAM) 1976-03-12
ES403435A1 (es) 1975-05-01
ZA723207B (en) 1973-03-28
PH12136A (en) 1978-11-07
FI55766C (fi) 1979-10-10
GB1405088A (en) 1975-09-03
DE2224534B2 (de) 1977-10-20
NL7207486A (OSRAM) 1972-12-05
ATA457772A (de) 1975-04-15
FI55766B (fi) 1979-06-29
DE2224534A1 (de) 1972-12-14
US4235870A (en) 1980-11-25
PH14809A (en) 1981-12-14
CH577830A5 (OSRAM) 1976-07-30
ES424533A1 (es) 1977-02-16
DK144306B (da) 1982-02-15
IL39430A (en) 1975-12-31
DE2224534C3 (de) 1981-04-02

Similar Documents

Publication Publication Date Title
NO138683C (no) Grunnmasse til anvendelse ved fremstilling av et farmasoeytisk preparat med langsom frigjoerelse av den aktive bestanddel
DK132303C (da) Fremgangsmade til fremstilling af en legemiddelform med retarderende virkning
NO142670C (no) Benzylpenicillinester for anvendelse som utgangsmateriale ved fremstilling av en terapeutisk virksom ester av alfa-aminobenzylpenicilliner
NL7502952A (nl) Vast therapeutisch preparaat voor inwendig gebruik.
NO138335C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkanolaminer
DK207575A (da) Legemiddel med psykotrop virkning dets anveldelse samt fremgangsmade til fremstilling deraf og af de aktive forbindelser deri
NO141804C (no) Fotopolymeriserbart preparat
NL155011B (nl) Werkwijze ter bereiding van een herbicide preparaat en werkwijze ter bereiding van daarbij toe te passen oxadiazolonderivaten.
DK132519C (da) Fremgangsmade til fremstilling af et stabilt medicinsk preparat indeholdende indomethacin samt beremedium til anvendelse ved fremgangsmaden
NO140977C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 2-amino-1,4-dihydropyridiner
NO137824C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylalkyltetrazoler
NO137899C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n (1h-tetrazol-5-yl)-kinaldamider
IL39212A (en) N-(dimethylaminomethylidene)-thiol and thiono-phosphoric acid ester imides,their preparation and their use as insecticides or acaricides
SE400551B (sv) Forfarande for framstellning av terapeutiskt aktiva 3-amino-5-karbamylbensoesyraderivat
NO136926C (no) Analogifremgangsm}te til fremstilling av terapeutisk aktive papaverinanaloger
SE396010B (sv) Forfarande for framstellning av aktiva emnen innehallande preparat med langvarig verkan i form av tabletter, drageer eller kapslar
NO137153C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive sulfamoylfenyl-pyrrolidoner
NO145383C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte indoler.
IT964380B (it) O fenil n alcossi tiuno fosfor fosfon estereammidi procedimento per la loro preparazione e loro impiego come insetticidi e acaricidi
DK144312C (da) Fremgangsmaade til fremstilling af et lactulosepulver til terapeutisk anvendelse
NO143795C (no) Kjemisk mellomprodukt for bruk ved fremstilling av terapeutisk aktive 2,6-metan-3-benzazosiner
BE833906A (fr) Compositions pharmaceutiques comprenant des canadensolides propres a la guerison des ulceres
SE394591B (sv) Forfarande for framstellning av ett farmaceutiskt preparat anvendbart vid behandling av depression, innehallande bl a l-tryptofan
NO144072C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 5-endo-(3-indolkarbonyloksy)-n-(amino-lavere-alkyl)-bicyklo-(82,2,1)-heptan-2,3-diendo-karboksylsyreimider
NO136198C (no) Analogifremgangsm}te ved fremstilling av terapeutisk aktivt 16-carboxy-17-methoxy-eburnan.